NM/CT 870 CZT

Bring theory to life with CZT
Bring theory to life with CZT
Introducing NM/CT 870 CZT, our third-generation, general purpose SPECT/CT system powered by CZT technology. It combines improvements in lesion detection1, image quality and patient comfort with advanced quantitative applications provided through Xeleris™. This latest generation offers an all-new SmartConsole and new CT features. Help bring your theories to life with a system designed to leverage all that CZT can do.
TECHNOLOGY

SPECT/CT as you have never seen it before

RESOLUTION

The resolution to discover something new

See everything clearly now

DESIGN

Designed to make every inch count

QUANTITATION

Quantitative SPECT/CT for every patient, every day

Built for quantitation

QUANTITATIVE APPLICATIONS

Inform your decisions with measurable results

  • Q. Volumetrix MI

    Q.Volumetrix MI enables routine quantitative SPECT results in the form of MBq/ml and SPECT SUV without workflow impediments for both base line and longitudinal studies.

  • Q. Volumetrix MI

    Q.Volumetrix MI integrates SUV measurements directly into the volume viewer, so you can see both results in the same application.

  • Q. Brain

    Accurately diagnose neurodegenerative diseases with Q.Brain.

  • DaTQUANT™

    Improve neurologic SPECT workflow with fast, reproducible and accurate quantitation of 123I Ioflupane with DaTQUANT.

  • Q. Lung

    Diagnose pulmonary embolism by identifying V/Q mismatch with Q.Lung.

  • Q. Lung

    Confidently classify patients eligible for lung resection surgeries with Q.Lung.

  • Dosimetry Toolkit

    Plan radioisotope therapy by measuring changes in tracer absorption over time with Dosimetry Toolkit.

SUMMARY

A SPECT/CT system for true discovery

Related Products

  • 1 In clinical practice, the use of NM/CT 870 CZT may improve lesion detectability depending on the clinical task, patient size, anatomical location and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose or scan time to obtain diagnostic image quality for the particular clinical task.
  • 2 Together with Clarity 2D and Evolution5 and compared to Discovery NM/CT 670 Pro/ES/DR without Clarity 2D and Evolution5. As demonstrated in phantom testing using a bone scan protocol, and the NEMA IEC Body Phantom. The actual time/dose reduction depends on the clinical task, patient size, anatomical location and clinical practice.
  • 3 At detector surface.
  • 4 Demonstrated in phantom testing using NEMA IEC Body Phantom at 50% scan times with Evolution5. Compared to Discovery NM/CT 670 Pro/ES/DR.
  • 5 In clinical practice, Evolution options5a (Evolution for Bone, Evolution for Cardiac, Evolution for Bone Planar) and Evolution Toolkit5b are recommended for use following consultation of a Nuclear Medicine physician, physicist and/or application specialist to determine the appropriate dose or scan time reduction to obtain diagnostic image quality for a particular clinical task, depending on the protocol adopted by the clinical site.
  • 5a Evolution Options - Evolution claims are supported by simulation of count statistics using default factory protocols and imaging of 99mTc based radiotracers with LEHR collimator on anthropomorphic phantom or realistic NCAT – SIMSET phantom followed by quantitative and qualitative images comparison.
  • 5b Evolution Toolkit - Evolution Toolkit claims are supported by simulation of full count statistics using lesion simulation phantom images based on various radiotracers and collimators and by showing that SPECT image quality reconstructed with Evolution Toolkit provide equivalent clinical information but have better signal-to-noise, contrast, and lesion resolution compared to the images reconstructed with FBP / OSEM.
  • 6 In clinical practice, the use of ASiR may reduce CT patient dose depending on the clinical task, patient size, anatomical location and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task.
  • 7 Quantitative accuracy defined as equivalence to well counter-measured injected activity in a test phantom. Equivalence means <11% difference when comparing measured counts in SPECT studies corrected by Q.AC-reconstructed CTAC to measured counts in studies corrected by benchmark reconstructed CTAC. Measured counts are defined as average within identical ROIs positioned on SPECT reconstructed slices of homogenous 99mTc solution phantom study.
  • 8 In clinical practice, the use of NM/CT 870 CZT may improve quantitation of lesions larger than 5.5 mL, depending on the clinical task, patient size, anatomical location and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose or scan time to obtain the claimed quantitation accuracy for the particular clinical task.